Intocare SB 50 Capsule contains Itraconazole 50 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections, including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, and aspergillosis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Intocare SB 50 Capsule is administered orally and is well-absorbed, with bioavailability enhanced when taken with food. It is metabolized primarily by the liver via the cytochrome P450 system and has a half-life of approximately 24 to 42 hours, allowing for convenient dosing schedules. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking medications that may interact with itraconazole, such as certain statins, benzodiazepines, and calcium channel blockers. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Intocare SB 50 Capsule should be used under medical supervision to ensure optimal efficacy and safety.